NFE2L2 and chronic kidney disease: Co-administration of osthole (40 mg/kg, intravenously) along with 2% adenine suspension attenuated inflammatory damage in a rat model of CKD through a mechanism that involved downregulation of NF-κB and TGFβ1 and activation of PI3K/Akt/Nrf2 signaling [124].